1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors

J. Li, Lin Shen, Yi Huang et al.|Annals of Oncology|2023

Cited by 0